Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Myomo, Inc. is a medical robotics company that designs, manufactures, and markets wearable powered orthotic devices intended to restore function and mobility to individuals with neuromuscular disorders. The company operates within the medical devices and rehabilitation technology industries, with a specific focus on upper-limb impairment caused by conditions such as stroke, spinal cord injury, brachial plexus injury, traumatic brain injury, and amyotrophic lateral sclerosis (ALS). Myomo’s core product is a non-invasive, externally worn robotic brace that uses electromyographic (EMG) signals from a patient’s muscles to assist movement.
The company’s primary revenue driver is the sale and reimbursement of its MyoPro® powered arm and elbow orthoses, which are prescribed by physicians and fitted through certified clinicians. Myomo primarily serves patients, rehabilitation hospitals, veterans, and clinics, with a significant portion of revenue tied to reimbursement from U.S. Medicare, the U.S. Department of Veterans Affairs (VA), private insurers, and workers’ compensation programs. Founded in 2004 as a spinout from research conducted at the Massachusetts Institute of Technology (MIT), Myomo has evolved from a research-focused startup into a commercial-stage medical device company following FDA clearance and expanded insurance reimbursement coverage.
Business Operations
Myomo operates as a single-reportable-segment medical device company focused on the development and commercialization of powered upper-limb orthotic systems. The company generates revenue primarily through direct billing to insurance providers and government healthcare programs after custom-fitting devices to individual patients. Sales are supported by a direct clinical sales force, patient advocacy outreach, and partnerships with rehabilitation professionals. Manufacturing is primarily outsourced, while product design, quality control, regulatory compliance, and commercialization are managed internally.
Operations are concentrated in the United States, which represents the vast majority of revenue, although Myomo also conducts limited international sales through distributors and subsidiaries. The company controls proprietary EMG-based control algorithms and mechanical designs that allow patients to initiate movement using their own muscle signals. Myomo maintains relationships with rehabilitation hospitals, VA medical centers, and orthotic and prosthetic clinics, which serve as referral and fitting channels for its devices.
Strategic Position & Investments
Myomo’s strategic focus centers on expanding insurance reimbursement coverage, increasing physician and patient awareness, and improving operating leverage through scale. Growth initiatives include expanding Medicare and private-payer coverage, deepening penetration within the VA healthcare system, and improving patient access through streamlined clinical and billing processes. The company continues to invest in product refinement, including lighter-weight designs, enhanced software, and improved ease of use for patients and clinicians.
Rather than pursuing large acquisitions, Myomo has historically focused on organic growth and internal technology development. The company operates international activities through Myomo Europe GmbH, which supports limited distribution and regulatory efforts outside the U.S. Emerging opportunities include broader adoption of wearable medical robotics, increased use of assistive technologies in home-based rehabilitation, and demographic trends tied to aging populations and stroke prevalence.
Geographic Footprint
Myomo is headquartered in Cambridge, Massachusetts, and its primary operational footprint is in North America, particularly the United States, where the majority of its patients, clinical partners, and reimbursement sources are located. The company maintains sales and clinical support personnel across multiple U.S. regions to support patient evaluations, fittings, and follow-up care.
Internationally, Myomo has a smaller presence in Europe through Myomo Europe GmbH, as well as distributor relationships in select additional markets. While international revenue currently represents a minor portion of total sales, the company maintains regulatory clearances and infrastructure to support longer-term global expansion, subject to reimbursement and market access conditions.
Leadership & Governance
Myomo was founded by John McBean, who helped translate MIT-based research into a commercial medical device platform. The company is led by an executive team with experience in medical devices, healthcare reimbursement, and commercial operations, with a strategic emphasis on disciplined growth, reimbursement expansion, and clinical adoption.
Key members of the leadership team include:
- Paul R. Gudonis – Chief Executive Officer
- Mark Elliott – Chief Financial Officer
- Joseph Walsh – Vice President of Sales
- Micah Pratt – Vice President of Product Development
The leadership team emphasizes patient-centered innovation, close collaboration with clinicians, and the development of sustainable reimbursement-driven business models to support long-term adoption of wearable medical robotics.